tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Recordati Publishes Half-Year Financial Report for 2025

Story Highlights
Recordati Publishes Half-Year Financial Report for 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) is now available.

Recordati has published its half-year financial report as of June 30, 2025, which has been approved by the Board of Directors and is now accessible to the public. This announcement underscores Recordati’s commitment to transparency and its strategic positioning in the pharmaceutical industry, potentially impacting stakeholders by providing insights into the company’s financial health and operational progress.

The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.

More about Recordati Industria Chimica e Farmaceutica SPA

Recordati Industria Chimica e Farmaceutica S.p.A. is an international pharmaceutical group with Italian origins, offering therapeutic options in specialty and general medicine, as well as rare diseases. The company is listed on the Italian Stock Exchange and operates in about 150 countries across the EMEA, Americas, and APAC regions, employing over 4,450 people.

Average Trading Volume: 289,011

Technical Sentiment Signal: Buy

Current Market Cap: €11.21B

See more insights into REC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1